# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

#### **CURRENT REPORT**

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): September 3, 2020

# DEXCOM, INC.

(Exact Name of the Registrant as Specified in Charter)

Delaware (State or Other Jurisdiction of Incorporation) 000-51222 (Commission File Number) 33-0857544 (IRS Employer Identification No.)

6340 Sequence Drive, San Diego, CA (Address of Principal Executive Offices)

92121 (Zip Code)

(858) 200-0200

(Registrant's telephone number, including area code)

(Former Name or Former Address, if Changed Since Last Report)

	ck the appropriate box below if the Form 8-K filing is inter- towing provisions:	nded to simultaneously satisfy the filin	g obligation of the registrant under any of the	
	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)			
	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)			
	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))			
	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))			
Securities registered pursuant to Section 12(b) of the Act:				
	Title of each class	Trading Symbol(s)	Name of each exchange on which registered	
Common Stock, \$0.001 par value per share		DXCM	Nas daq Global Select Market	
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).				
Eme	erging growth company $\square$			
	f an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act			

#### Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

On September 3, 2020, the Board of Directors of DexCom, Inc. (the "Company") amended and restated the Company's Amended and Restated Bylaws (the "Amended and Restated Bylaws") to adopt a provision designating (i) the Delaware Chancery Court as the exclusive forum for certain internal corporate claims, and (ii) the federal district courts of the United States as the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act of 1933, as amended.

The foregoing summary and description of the provisions of the Amended and Restated Bylaws does not purport to be complete and is qualified in its entirety by reference to the full text of the Amended and Restated Bylaws, a copy of which is filed as Exhibit 3.1 with this Current Report on Form 8-K and is incorporated herein by reference.

#### Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

- 3.1 Amended and Restated Bylaws
- 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

### DEXCOM, INC.

By: /s/ Patrick M. Murphy

Patrick M. Murphy
Executive Vice President and Chief Legal Officer

Date: September 9, 2020